RedHill Biopharma receives complete response letter from FDA for acute migraines drug
RHB-103 is a proprietary oral thin film formulation of rizatriptan benzoate, a 5-HT1 receptor agonist and the active drug in Merck & Co.’s Maxalt. A CRL is issued
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
MSC’s full sports nutrition product range is available to purchase online, and sits alongside an interactive expertise facility that gives visitors the opportunity to access to their multidisciplinary
The purchase order is through Axxess Pharmas wholly-owned subsidiary, AllStar Health Brands. Private Label Nutraceuticals vice-president of sales Kevin Harden noted as an industry leading contract manufacturer of
The new deal is focused on the discovery and development of several predefined Nanobody candidates (including bi- and tri-specifics) directed toward ‘immune checkpoint modulators’. Immune checkpoint modulators are
The acquisition gives AstraZeneca ownership of the intellectual property and global rights for the development, manufacture and commercialisation of the diabetes business, including Onglyza, Kombiglyze XR, Komboglyze, dapagliflozin,